Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 3
2009 2
2010 1
2011 1
2012 4
2013 8
2014 4
2015 9
2016 9
2017 4
2018 13
2019 14
2020 21
2021 13
2022 15
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
The prognostic and therapeutic potential of HO-1 in leukemia and MDS.
Sadeghi M, Fathi M, Gholizadeh Navashenaq J, Mohammadi H, Yousefi M, Hojjat-Farsangi M, Namdar A, Movasaghpour Akbari AA, Jadidi-Niaragh F. Sadeghi M, et al. Among authors: hojjat farsangi m. Cell Commun Signal. 2023 Mar 13;21(1):57. doi: 10.1186/s12964-023-01074-8. Cell Commun Signal. 2023. PMID: 36915102 Free PMC article. Review.
Promising immunotherapy: Highlighting cytokine-induced killer cells.
Shirjang S, Alizadeh N, Mansoori B, Mahmoodpoor A, Kafil HS, Hojjat-Farsangi M, Yousefi M. Shirjang S, et al. Among authors: hojjat farsangi m. J Cell Biochem. 2019 Jun;120(6):8863-8883. doi: 10.1002/jcb.28250. Epub 2018 Dec 16. J Cell Biochem. 2019. PMID: 30556298 Review.
Berberine: A novel therapeutic strategy for cancer.
Samadi P, Sarvarian P, Gholipour E, Asenjan KS, Aghebati-Maleki L, Motavalli R, Hojjat-Farsangi M, Yousefi M. Samadi P, et al. Among authors: hojjat farsangi m. IUBMB Life. 2020 Oct;72(10):2065-2079. doi: 10.1002/iub.2350. Epub 2020 Jul 31. IUBMB Life. 2020. PMID: 32735398 Free article. Review.
The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia.
Abolhasani S, Hejazian SS, Karpisheh V, Khodakarami A, Mohammadi H, Gholizadeh Navashenaq J, Hojjat-Farsangi M, Jadidi-Niaragh F. Abolhasani S, et al. Among authors: hojjat farsangi m. IUBMB Life. 2023 Mar;75(3):257-278. doi: 10.1002/iub.2660. Epub 2022 Jul 18. IUBMB Life. 2023. PMID: 35848163 Free article. Review.
Oncostatin M: A mysterious cytokine in cancers.
Masjedi A, Hajizadeh F, Beigi Dargani F, Beyzai B, Aksoun M, Hojjat-Farsangi M, Zekiy A, Jadidi-Niaragh F. Masjedi A, et al. Among authors: hojjat farsangi m. Int Immunopharmacol. 2021 Jan;90:107158. doi: 10.1016/j.intimp.2020.107158. Epub 2020 Nov 10. Int Immunopharmacol. 2021. PMID: 33187910 Review.
Nanomedicine for improvement of dendritic cell-based cancer immunotherapy.
Hashemi V, Farhadi S, Ghasemi Chaleshtari M, Seashore-Ludlow B, Masjedi A, Hojjat-Farsangi M, Namdar A, Ajjoolabady A, Mohammadi H, Ghalamfarsa G, Jadidi-Niaragh F. Hashemi V, et al. Among authors: hojjat farsangi m. Int Immunopharmacol. 2020 Jun;83:106446. doi: 10.1016/j.intimp.2020.106446. Epub 2020 Mar 31. Int Immunopharmacol. 2020. PMID: 32244048 Review.
CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-Farsangi M, Azizi G, Yousefi M, Jadidi-Niaragh F. Ghalamfarsa G, et al. Among authors: hojjat farsangi m. Expert Opin Ther Targets. 2019 Feb;23(2):127-142. doi: 10.1080/14728222.2019.1559829. Epub 2018 Dec 26. Expert Opin Ther Targets. 2019. PMID: 30556751 Review.
The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies.
Sadeghi M, Khodakarami A, Ahmadi A, Fathi M, Gholizadeh Navashenaq J, Mohammadi H, Yousefi M, Hojjat-Farsangi M, Movasaghpour Akbari AA, Jadidi-Niaragh F. Sadeghi M, et al. Among authors: hojjat farsangi m. Expert Opin Ther Targets. 2022 Dec;26(12):1057-1071. doi: 10.1080/14728222.2022.2170781. Epub 2023 Jan 24. Expert Opin Ther Targets. 2022. PMID: 36683579 Review.
CDK1 in Breast Cancer: Implications for Theranostic Potential.
Izadi S, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, Yousefi M, Jadidi-Niaragh F. Izadi S, et al. Among authors: hojjat farsangi m. Anticancer Agents Med Chem. 2020;20(7):758-767. doi: 10.2174/1871520620666200203125712. Anticancer Agents Med Chem. 2020. PMID: 32013835 Review.
The molecular biology and therapeutic potential of Nrf2 in leukemia.
Khodakarami A, Adibfar S, Karpisheh V, Abolhasani S, Jalali P, Mohammadi H, Gholizadeh Navashenaq J, Hojjat-Farsangi M, Jadidi-Niaragh F. Khodakarami A, et al. Among authors: hojjat farsangi m. Cancer Cell Int. 2022 Jul 29;22(1):241. doi: 10.1186/s12935-022-02660-5. Cancer Cell Int. 2022. PMID: 35906617 Free PMC article. Review.
109 results